Cancer cells and patients demonstrate resistance to clinically used agents as a result of the expression of the drug efflux pump P-glycoprotein (Pgp) and the βIII-tubulin isotype [2,18,19], leading to efforts to identify new MTAs that can overcome these mechanisms of drug resistance. This evidence concerns the gene PGP and cancer.